CINECA IRIS Institutional Research Information System

GRAGNANI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.503
NA - Nord America 632
AS - Asia 356
AF - Africa 29
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.527
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 1.210
US - Stati Uniti d'America 625
SG - Singapore 168
SE - Svezia 98
CN - Cina 80
CH - Svizzera 72
IN - India 67
DE - Germania 39
CI - Costa d'Avorio 24
PL - Polonia 22
GB - Regno Unito 21
HK - Hong Kong 20
BG - Bulgaria 13
CZ - Repubblica Ceca 10
CA - Canada 7
FI - Finlandia 7
TR - Turchia 6
BR - Brasile 5
JP - Giappone 5
VN - Vietnam 5
SN - Senegal 3
TW - Taiwan 3
AT - Austria 2
FR - Francia 2
IE - Irlanda 2
NG - Nigeria 2
RU - Federazione Russa 2
TH - Thailandia 2
CL - Cile 1
DK - Danimarca 1
EU - Europa 1
NL - Olanda 1
UA - Ucraina 1
Totale 2.527
Salva come PNG Salva come JPEG
Città #
Milan 778
Boardman 137
Pisa 111
New York 105
Singapore 92
Rome 82
Bern 72
Hyderabad 59
Fairfield 57
Seattle 42
Ashburn 36
Frankfurt am Main 33
Woodbridge 31
Florence 26
Abidjan 24
Warsaw 22
Chicago 21
Hong Kong 18
Houston 18
Shanghai 18
Wilmington 17
Cambridge 15
Chandler 15
Ann Arbor 14
Serra 14
Sofia 13
London 12
Fuzhou 9
Brno 8
Ottawa 7
Pune 7
Beijing 5
Lawrence 5
Medford 5
Princeton 5
Tokyo 5
Chiswick 4
Des Moines 4
Istanbul 4
Nocera Superiore 4
Santa Clara 4
Dakar 3
Lappeenranta 3
Ogden 3
Quanzhou 3
San Diego 3
São Paulo 3
Tübingen 3
Bremen 2
Capaccio 2
Carrara 2
Castano Primo 2
Clemson 2
Dearborn 2
Dublin 2
Fort Worth 2
Fossombrone 2
Gainesville 2
Izmir 2
Lagos 2
Nanjing 2
Padova 2
Paris 2
Pontedera 2
Seravezza 2
Springfield 2
Taichung 2
Taubaté 2
Udon Thani 2
Vienna 2
Viterbo 2
Wenzhou 2
Čelákovice 2
Altopascio 1
Bhubaneswar 1
Clifton 1
Dallas 1
Dongguan 1
Genoa 1
Guangzhou 1
Hackney 1
Heze 1
Jiaxing 1
Kent 1
Kilburn 1
Laojunmiao 1
Livorno 1
Longshan 1
Los Angeles 1
Modena 1
Nanchang 1
Plymouth Meeting 1
Prescot 1
San Francisco 1
Santiago 1
Shenzhen 1
Southwark 1
Taipei 1
Tangshan 1
Torino 1
Totale 2.056
Salva come PNG Salva come JPEG
Nome #
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 94
B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma 85
Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection 77
HCV-related rheumatic manifestations and therapeutic strategies 77
Treatment of HCV-related mixed cryoglobulinemia 75
IgG cryoglobulinemia 67
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups 54
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 48
Could the presence of Mixed Cryoglobulinemia influence the outcome of standard peg-IFN plus ribavirin anti-HCV therapy? 47
MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA 46
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study 46
HCV infection, malignancy and liver transplantation 46
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 46
Long-term outcome of HCV-related mixed cryoglobulinemia in patients achieving sustained viral sustained viral response (SVR) after antiviral therapy 45
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 45
Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26 44
A serum metabolomic analysis of HCV-infected patients successfully treated with IFN-free DAA regimens 44
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 44
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 43
Plasma PAF-AH biological activity decreases in patients with HCV chronic infection 43
Non-Invasive B-Cell Clonality Markers May Help in the Rational Approach to HCV Svr Cryoglobulinemic Patients with Persisting Manifestations 43
Detection of WA B Cells in HCV Infection by Molecular Analysis: A Prognostic Marker for Cryoglobulinemic Vasculits and B Cell Lymphomas 42
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 42
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 41
HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1 41
The Hepatitis C Virus Infection as a Systemic Disease 41
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies 41
P0752 : NOTCH4 and MHC class II polymorphisms contibute to HCV-related benign and malignant lymphoproliferative diseases 41
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 40
Host genetic determinants in HCV-related mixed cryoglobulinemia 40
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 40
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 40
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 40
Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis 40
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 40
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 40
HCV-related lymphatic and hepatic malignancies are associated with different microRNA expression patterns in PBMCs 40
Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients 39
Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection 39
Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? 39
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 39
Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study 38
HCV and lymphoproliferation 38
Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection 38
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment 37
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 37
NOTCH4 AND MHC CLASS II POLYMORPHISMS CONTRIBUTE TO HCV-RELATED BENIGN AND MALIGNANT LYMPHOPROLIFERATIVE DISEASES 36
Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series 28
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases 28
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 26
COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity 25
Thyroid Autoimmunity and SARS-CoV-2 Infection 22
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 20
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 20
DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer 17
HCV AND lymphoma: Genetic and epigenetic factors 17
Assessment of Free Light Chains in HCV positive patients undergoing Rituximab treatment 17
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies 16
Serological and Molecular Characterization of Hepatitis C Virus-Related Cryoglobulinemic Vasculitis in Patients without Cryoprecipitate 14
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 14
MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA 14
Host genetic determinants in HCV-related mixed cryoglobulinemia 13
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 13
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study 13
Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature 12
Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy 12
IL28B POLYMORPHISM AS PREDICTOR OF RESPONSE TO ANTI-HCV THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME 12
High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy 11
Dual stimulation by autoantigen and CpG fosters the proliferation of exhausted rheumatoid factor-specific CD21low B cells in hepatitis C virus-cured mixed cryoglobulinemia 10
Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life 10
A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders 10
Hepatitis C virus lymphotrophism: lessons from a decade of studies 10
Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study 10
Free light chains: Eclectic multipurpose biomarker 10
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 9
Role of notch receptors in hematologic malignancies 8
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia 7
The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis 6
Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis 6
HCV infection and carotid atherosclerosis: evidence in favour of a local viral action inside the plaque 6
Hepatitis b virus-related cryoglobulinemic vasculitis: Review of the literature and long-term follow-up analysis of 18 patients treated with nucleos(t)ide analogues from the italian study group of cryoglobulinemia (gisc) 5
HIGH SVR RATES WITH SMV plus SOF IN HCV GT1 AND GT4 PATIENTS WITH CIRRHOSIS OR ADVANCED FIBROSIS: A REAL PRACTICE ANALYSIS FROM A LARGE REGIONAL DATABASE IN TUSCANY, ITALY 4
PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases 4
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 4
Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis 4
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 4
HCV-RELATED MIXED CRYOGLOBULINEMIA: DATA FROM PITER, A NATIONWIDE ITALIAN HCV COHORT STUDY 4
Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: Preliminary results of a prospective pilot study 4
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 4
Hepatitis C Virus infection in the immunocompromised host: a complex scenario with variable clinical impact 3
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 3
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 3
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 3
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 3
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 3
Prevalence of bcl-2 recombination in hepatitis C virus-related mixed cryoglobulinemia with or without complicating B-cell lymphoma 3
BAFF, BAFF promoter and BAFF receptor allelic variants in HCV-related Mixed Cryoglobulinemia and Non Hodgkin's Lymphoma 3
Developmentally regulated expression of the mouse homologues of the potassium channel encoding genes m-erg 1, m-erg 2 and m-erg 3 3
A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders 3
IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection 3
Totale 2.724
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.286
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.286
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202078 0 0 0 0 10 10 9 9 24 7 5 4
2020/202136 5 3 4 2 0 0 0 5 1 6 5 5
2021/202275 0 1 5 4 8 15 1 6 2 12 5 16
2022/2023449 8 6 10 4 4 11 257 19 87 11 23 9
2023/20241.613 277 230 325 178 248 134 20 26 5 22 12 136
2024/2025432 126 134 40 122 10 0 0 0 0 0 0 0
Totale 2.806